Overview

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Status:
Unknown status

Trial end date:
2018-06-15

Target enrollment:

Participant gender:

Summary

This is a multicentric, phase II single-arm study in which KRAS, NRAS and BRAF wild-type, irinotecan-resistant metastatic colorectal cancer patients progressing after an initial response to a first-line cetuximab-containing therapy, receive a rechallenge third-line treatment with cetuximab plus irinotecan.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Oncologico del Nord-Ovest

Treatments:

Camptothecin
Cetuximab
Irinotecan